Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions

Sten Myrehaug, Arjun Sahgal, Suzanne M. Russo, Simon S. Lo, Lauren M. Rosati, Nina A. Mayr, Michael Lock, William Small, Jennifer A. Dorth, Rodney J. Ellis, Bin S. Teh, Joseph M. Herman

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


ABSTRACT: Despite advances in surgical, medical, and radiation therapy for pancreatic cancer, the prognosis remains poor. At this time, the only chance for long-term survival is surgical resection. More challenging is the optimal management of unresectable locally advanced pancreatic cancer, which has historically been treated with concurrent chemoradiation or chemotherapy alone. However, the survival and local control benefit of conventional radiotherapy in addition to chemotherapy was unclear. More recently, stereotactic body radiotherapy (SBRT) is emerging as a viable approach to maximizing local tumor control with a tolerable side effect profile. SBRT achieves sharp dose fall-off facilitating safe delivery of highly focused radiation to the tumor over 1-5 days. Although the optimal regimen of pancreas SBRT has not yet been established, its short treatment course limits the delay of additional. Future directions involve prospective study of pancreas SBRT and exploration of biomarkers and imaging technology in order to adopt a personalized management paradigm.

Original languageEnglish (US)
Pages (from-to)523-530
Number of pages8
JournalExpert Review of Anticancer Therapy
Issue number5
StatePublished - May 3 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions'. Together they form a unique fingerprint.

Cite this